• Slide Title

    Magvita rTMS Therapy Approved by NICE for Depression Treatment

rTMS Depression Treatment NICE Approved

The National Institute for Health and Care Excellence (NICE) in the UK has now approved rTMS (Repetitive Transcranial Magnetic Stimulation) as an effective and safe method of treating depression for patients in the UK. Repetitive Transcranial Magnetic Stimulation (rTMS) is a treatment which uses pulsing magnetic fields to activate brain centers associated with mood. The treatment has a number of advantages over traditional medication as it is non-invasive. It does not involve surgery, anesthesia or sedation and it does not have the side effects associated with antidepressants. rTMS has also been shown effective in treating migraine, post-natal depression and pain.

The guidelines issued by NICE have not specified or restricted the type of rTMS treatment, which means that practitioners can offer treatment using conventional rTMS – which takes around 40 minutes per session – and/or theta burst, which takes around 5 minutes.

Ectron are the UK exclusive distributors of Magventure's rTMS system known as Magvita. This is the only system that has been awarded a CE mark for clinical use. 
 NICE (The UK National Institute of Health and Care Excellence) has – as of December 2015 – issued full guidance to the NHS on rTMS as a treatment for depression: “The evidence on repetitive transcranial magnetic stimulation for depression shows no major safety
concerns [...] repetitive transcranial magnetic stimulation for depression may be used with normal arrangements for clinical governance and audit.”

To read the NICE Guidelines in full click here
Share by: